Editorial team of Nature Reviews Drug Discovery
www.nature.com/nrd
Nature Reviews Drug Discovery
Loading...
A guide to effective drug development through nonprofit models
www.nature.com/articles/d41...
Patient organizations are reshaping rare disease drug development. Based on a survey, interviews and experience, this article discusses how to direct resources toward drug development goals
Antiviral peptide nabs FDA approval for hepatitis delta virus infection
www.nature.com/articles/d41...
Gilead’s bulevirtide is the first treatment for the potentially fatal infection
For readers interested in next-generation GLP-1-based therapies for diabetes, obesity and more, here's a review
nature.com/articles/s41...
rdcu.be/fnl3W
Our June issue is live! Read about the therapeutic potential of orphan GPCRs, wearable technologies in clinical trials for drug development, a renaissance in targeting the PI3K/AKT/mTOR pathway and more here www.nature.com/nrd/volumes/...
Therapeutic and prophylactic strategies for Ebola caused by Bundibugyo virus
www.nature.com/articles/d41...
This new article argues that the ongoing Ebola outbreak should be a turning point for moving R&D towards species-inclusive and broadly applicable filovirus countermeasures
Better data for better medicines: a path to data-driven medicines regulation
www.nature.com/articles/d41...
This new Comment article highlights how the EU medicines regulatory system is becoming more data-driven
Novel drug targets in 2025
www.nature.com/articles/d41...
This new article highlights 11 targets not previously modulated by approved drugs
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments. www.statnews.com/2026/06/08/a...
Evolution of the psoriasis therapy landscape
www.nature.com/articles/d41...
This new article analyses the pipeline of drugs for psoriasis and their market impact, highlighting the growing importance of oral therapies
Towards mRNA therapeutics 2.0
www.nature.com/articles/s41...
This new Review discusses progress and insights from clinical studies on mRNA-based drugs, including enzyme replacement therapies, cancer immunotherapies, genome-modifying therapies and immune cell reprogramming therapies
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.
